Resource Summary Report

Generated by NIF on Sep 11, 2026

AsPC-1

RRID:CVCL_0152
Type: Cell Line

Proper Citation

RRID:CVCL_0152

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0152

Proper Citation: RRID:CVCL_0152

Description: Cell line AsPC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: PMID:1630814, PMID:1764370, PMID:4023565, PMID:6582512, PMID:7182348, PMID:7972006, PMID:8026879, PMID:8194712, PMID:8286197, PMID:9331070, PMID:9665481, PMID:10027410, PMID:10408907, PMID:11115575, PMID:11169959, PMID:11787853, PMID:12692724, PMID:14695172, PMID:15126341, PMID:15367885, PMID:15688027, PMID:15770730, PMID:16912165, PMID:18298655, PMID:18380791, PMID:20037478, PMID:20164919, PMID:20215515, PMID:20418756, PMID:21607521, PMID:22460905, PMID:22585861, PMID:25167228, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26216984, PMID:26586397, PMID:26589293, PMID:27259358, PMID:27397505, PMID:27910856, PMID:28196595, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:32782605, PMID:35839778

Comments: Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AsPC-1

Synonyms: AsPc-1, Aspc-1, ASPC-1, As-PC1, ASPC1, AsPC1, Aspc1, AsPc1

Cross References: BTO:BTO_0001864, CLO:CLO_0001756, EFO:EFO_0002112, MCCL:MCC:0000044, CLDB:cl289, AddexBio:C0018023/5061, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1682, BCRC:60494, BioGRID_ORCS_Cell_line:259, BioSample:SAMN03471961, BioSample:SAMN10988235, cancercelllines:CVCL_0152, CCRID:1101HUM-PUMC000214, CCRID:3101HUMTCHu8, Cell_Model_Passport:SIDM00899, CGH-DB:160-1, CGH-DB:9271-4, ChEMBL-Cells:CHEMBL3307994, ChEMBL-Targets:CHEMBL612588, CLS:300158, Cosmic:707247, Cosmic:710851, Cosmic:724645, Cosmic:808166, Cosmic:868239, Cosmic:872994, Cosmic:910702, Cosmic:913308, Cosmic:918050, Cosmic:922255, Cosmic:923164, Cosmic:932514, Cosmic:933515, Cosmic:947398, Cosmic:948371, Cosmic:948740, Cosmic:949230, Cosmic:1006364, Cosmic:1090374, Cosmic:1108341, Cosmic:1198210, Cosmic:1320465, Cosmic:1366285, Cosmic:1477433, Cosmic:1571783, Cosmic:1644318, Cosmic:1995341, Cosmic:2434085, Cosmic:2668289, Cosmic-CLP:910702, DepMap:ACH-000222, ECACC:96020930, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910702, GEO:GSM206446, GEO:GSM383935, GEO:GSM495808, GEO:GSM621911, GEO:GSM784702, GEO:GSM886870, GEO:GSM887935, GEO:GSM1024396, GEO:GSM1177959, GEO:GSM1177960, GEO:GSM1177961, GEO:GSM1374394, GEO:GSM1374395, GEO:GSM1374396, GEO:GSM1588607, GEO:GSM1588619, GEO:GSM1669603, GEO:GSM1906985, GEO:GSM1906986, GEO:GSM1906987, IARC_TP53:311, IARC_TP53:21127, IBRC:C10154, IGRhCellID:AsPC1, IZSLER:BS TCL 171, KCLB:21682, LiGeA:CCLE_008, LINCS_LDP:LCL-1730, NCBI_Iran:C558, PharmacoDB:AsPC1_67_2019, PRIDE:PXD003198, PRIDE:PXD030304, PRIDE:PXD032263, Progenetix:CVCL_0152, PubChem_Cell_line:CVCL_0152, SKY/M-FISH/CGH:1997, Wikidata:Q54750736

ID: CVCL_0152

Record Creation Time: 20220427T215223+0000

Record Last Update: 20260905T184649+0000

Ratings and Alerts

No rating or validation information has been found for AsPC-1.

No alerts have been found for AsPC-1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 894 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and ??3??1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Cancer research, 86(1), 99.

Castelli S, et al. (2026) IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy. Immunity, 59(1), 195.

Armstrong A, et al. (2026) Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 611.

Anh DXT, et al. (2026) GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(14), e14735.

Miyan J, et al. (2026) The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing apoptosis induction. bioRxiv : the preprint server for biology.

Shi X, et al. (2026) Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia. Cancer cell, 44(5), 949.

Wang J, et al. (2026) Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING. Signal transduction and targeted therapy, 11(1), 44.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell reports. Medicine, 7(4), 102688.

Qian Y, et al. (2026) Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis. Cell death & disease, 17(1).

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. iScience, 29(6), 115978.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer research, 86(8), 1868.

Lu T, et al. (2026) Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. Communications biology, 9(1), 260.

De Boni L, et al. (2026) Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors. iScience, 29(3), 114954.

Zhang H, et al. (2026) Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer. Cancer & metabolism, 14(1).

Shi M, et al. (2026) Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma. Genome research, 36(2), 275.

Li Z, et al. (2026) An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(24), e15606.

Wu Y, et al. (2026) The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Mediators of inflammation, 2026(1), e2632235.

Shen S, et al. (2026) ALDH1A3 promotes the lung metastatic organotropism of pancreatic ductal adenocarcinoma through semaphorin signaling. iScience, 29(6), 115950.

Shi X, et al. (2026) Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e20029.